The Institute for Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has announced a new partnership to launch The Centre for Mental Health Research and Innovation, in collaboration with COMPASS Pathways and The South London and Maudsley NHS Foundation Trust, to accelerate psychedelic research and develop new models of care for mental health in the U.K.
Category Press Release
Published in King's College London
Country United Kingdom
Companies FeaturedSouth London and Maudsley NHS Foundation Trust
The South London and Maudsley NHS Foundation Trust provide the widest range of NHS mental health services in the UK. The trust has recently expanded its research into psychedelic therapies.
King's College London
KCL is home to the Psychedleic Trials Group.
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.